The Banking Executive, Issue 155, November 2021

2021 G20 Rome Summit mandate throughout 2022 and acknowledge the formation of the Multilateral Leaders Task Force on COVID-19. We wel- come the work undertaken by the COVAX ACT-A Facilitation Council Vaccine Manufacturing Working Group and its report aimed at creating a broader base for vaccine manufacturing. In particular, we will support in- creasing vaccine distribution, ad- ministration and local manufacturing capacity in LMICs, including through tech- nology transfer hubs in various regions, such as the newly estab- lished mRNA Hubs in South Africa, Brazil and Argentina, and through joint production and processing arrangements. We will work together towards the recognition of COVID-19 vac- cines deemed safe and effica- cious by the WHO and in accordance with national legis- lation and circumstances, and to strengthen the organization's ability regarding approval of vac- cines, including optimizing pro- cedures and processes, with the aim of broadening the list of vac- cines authorized for emergency use (EUL), while continuing to protect public health and ensur- ing privacy and data protection. As a collective G20 effort, and in light of the enduring vaccination gaps, we commit to substantially increase the provision of and ac- cess to vaccines, as well as to therapeutics and diagnostics. We will enhance our efforts to en- sure the transparent, rapid and predictable delivery and uptake of vaccines where they are needed. We call on the private sector and on multilateral finan- cial institutions to contribute to this endeavor. We acknowledge the work of the World Bank Group in this respect and of the IMF and the WHO through the vaccine supply forecast dash- board. 6. We reaffirm our commitment to the Global Health Summit Rome Declaration as a compass for collective action and are com- mitted to strengthening global health governance. We support the ongoing work on strengthen- ing the leading and coordination role of an adequately and sus- tainably funded WHO. We ac- knowledge that financing for pandemic prevention, prepared- ness and response (PPR) has to become more adequate, more sustainable and better coordi- nated and requires a continuous cooperation between health and finance decision-makers, includ- ing to address potential financing gaps, mobilizing an appropriate mix of existing multilateral fi- nancing mechanisms and ex- plore setting up new financing mechanisms. We establish a G20 Joint Finance-Health Task Force aimed at enhancing dialogue and global cooperation on issues relating to pandemic PPR, pro- moting the exchange of experi- ences and best practices, developing coordination arrangements between Finance and Health Ministries, promoting collective action, assessing and addressing health emergencies with cross-border impact, and encouraging effective steward- ship of resources for pandemic PPR, while adopting a One Health approach. Within this context, this Task Force will work, and report back by early 2022, on modalities to establish a financial facility, to be de- signed inclusively with the cen- tral coordination role of the WHO, G20-driven and engaging from the outset Low- and Mid- dle-Income Countries, additional non-G20 partners and Multilat- eral Development Banks, to en- sure adequate and sustained financing for pandemic preven- tion, preparedness and response. 7. We reaffirm our commitment to achieve the health-related SDGs, in particular Universal Health Coverage. We welcome multilat- eral efforts aimed at supporting and strengthening pandemic pre- paredness and response, includ- ing consideration of a possible international instrument or agreement in the context of the WHO, and at strengthening im- plementation of and compliance with the International Health Regulations 2005. We commit to pursue a One Health approach at global, regional, national and local levels. To this end, we will enhance global surveillance, early detection and early warn- ing systems, under the coordinat- ing role of the WHO, FAO, OIE and UNEP, and address risks emerging from the human-ani- mal-environment interface, par- ticularly the emergence of zoonotic diseases, while pursu- ing global efforts to fight antimi- crobial resistance, while ensuring access to antimicrobials and their prudent stewardship, and continuing to address other critical issues, including non- communicable diseases and mental health. Acknowledging the importance of swiftly react- ing to pandemics, we will sup- port science to shorten the cycle for the development of safe and effective vaccines, therapeutics and diagnostics from 300 to 100 days following the identification of such threats and work to make them widely available. 8. We reaffirm the importance of ensuring the continuity of health services beyond COVID-19 and of strengthening national health systems and primary health care services, in light of the repercus- sions of the pandemic on mental health and well-being, due to isolation, unemployment, food insecurity, increased violence against women and girls and constrained access to education as well as health services, in- cluding sexual and reproductive health, paying special attention to women and girls and to the the BANKING EXECUTIVE 38 ISSUE 155 NOVEMBER 2021